Abstract: Fluorosilicone fluids useful as high-density fluid ocular tamponades and methods of producing, purifying and using the fluorosilicone fluids in an ocular surgical procedure for retinal treatment.

Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders

Abstract: A solid phase synthetic method for preparing arylretinamides is provided. The method comprises reacting hexachloroacetone with a solvent-suspended resin-bound triphenylphosphine to provide a suspension comprising an activated chlorinating reagent; reacting retinoic acid with the activated chlorinating reagent to provide retinoyl chloride; adding pyridine and a select arylamine to the resulting mixture; and stirring the resulting mixture for a time and at a temperature sufficient for the select arylamine to react with the retinoyl chloride and provide the arylretinamide. Also provided, are select arylretinamides that can be prepared by the present method, and methods of using such arylretinamides to induce apoptosis in cancer cells.

Abstract: Compounds of formula (I) are novel P2X3 and P2X2/P2X3 containing receptor antagonists and are useful in treating pain, urinary incontinence, and bladder overactivity.

Abstract: The invention provides a novel method for synthesizing Morphine-6-Glucuronide comprising the step of reacting 3-O-pivaloyloxymorphine and methyl 1&agr;,2-ethylorthopivalate-3,4-di-O-pivaloylglucouronate.

Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.

Abstract: A method of reducing adhesion at a site of trauma includes forming a film from an alginate solution, contacting the film with a cross-linking solution to form a cross-linked mechanically stable sheet, and placing at least a portion of the sheet at the site of trauma. An anti-adhesion barrier includes a sheet of ionically cross-linked alginate having a thickness in a range of 0.25 mm to 10 mm. The sheet has a tear strength sufficient for suturing and repositioning. A drug delivery device includes a cross-linked alginate container that can be filled with a drug.

Abstract: Described is a process for the preparation of compounds of formula (1a) which comprises reacting an isomeric mixture consisting of from 75 to 95% of compound of formula (2a) and from 5 to 25% of a compound of formula (2b) with methylamine, in a suitable solvent, to form a sertraline-imine isomeric mixture consisting of from 75 to 95% of formula (1a) and from 5 to 25% of formula (1b)(A1), or reacting an isomeric mixture consisting of from 75 to 95% of a compound of formula (2a) and from 5 to 25% of a compound of formula (2b) with methylamine, in a suitable solvent, using suitable methods of isolation to form an enriched sertraline-imine isomeric mixture, consisting of >99% of a compound of formula (1a) and <1% of a compound of formula (1b)(A2); and then subjecting the sertraline-imine isomeric mixture obtained according to reaction route (A1) or (A2), in a suitable solvent, to recrystallisation (B), in accordance with scheme (I) wherein in formula (1a), R1, R2 and R3 are each independently of the others

Abstract: A method for producing biphenols by oxidative coupling of dialkylphenols which proceeds in two stages using a copper amine complex which is catalytically effective in each stage is disclosed. A novel copper amine complex is also disclosed wherein the complex exhibits high catalytic activity for the oxidative coupling of substituted phenols under mild conditions, has dual (two stage) activity and can be readily recycled and reused.

Abstract: An integrated process for preparing &agr;-(2,4-disulfophenyl)-N-tert-butylnitrone and its salts is disclosed in which N-tert-butylhydroxylamine acid addition salt is incompletely neutralised so as to leave catalytic amounts of acid and the neutralisation product is condensed with an appropriate aldehyde.

Abstract: A process for producing an optically active amino alcohol is provided that includes a step in which a nitro ketone or a cyano ketone is reacted with a hydrogen-donating organic or inorganic compound in the presence of a transition metal compound catalyst having an optically active nitrogen-containing compound as an asymmetric ligand to give an optically active nitro alcohol or an optically active cyano alcohol, and a step in which the above optically active alcohol is further reduced to efficiently produce an optically active amino alcohol.

Abstract: Described herein are novel 1-aryl-3-(2-chloroalkanylureas derivatives. These derivatives are useful anticaner agents having excellent specifilty towards cell targets and potent antineoplastic activity without systemic toxicity derivatives mutagenicity. More specifically, the invention is directed to novel derivatives of the following formula: wherein R1 is C1-C6 alkyl, C3-C7 cycloalkyl, C1-C6 alkoxy, C1-C6 hydroxy alkyl, or C1-C6 halide; R2 is H, C1-C6 alky, C3-C7 cycloalkyl, C1-C6 I alkoxy, C1-C6 hydroxy alkyl or C1-C6 halide, di-halide or tri-halide; R1 and R2 may also be part of cyclic structures.

Abstract: A method is provided for making aromatic-imide and aromatic-methylidynetrissulfonyl species by reaction of aromatic species with a reactant according to formula (I): (X—SO2—)m—QH—(—SO2—R1)n  (I) wherein Q is C or N; wherein each X is independently selected from the group consisting of halogens, typically F or Cl; wherein each R1 is independently selected from the group consisting of aliphatic and aromatic groups, which may or may not be saturated, unsaturated, straight-chain, branched, cyclic, heteroatomic, polymeric, halogenated, fluorinated or substituted; wherein m is greater than 0; wherein m+n=2 when Q is N; and wherein m+n=3 when Q is C. Ar may be derived from an aromatic polymeric compound.

Abstract: This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Abstract: The invention relates to an installation for the preparation of urea from ammonia and carbon dioxide, the installation comprising two reactor sections in a vertically placed combined reactor and a high-pressure condenser section. The installation may comprise a vertically placed combined reactor, with the two reactor sections being separated by a high-pressure condenser section. In another embodiment the installation comprises a vertically placed combined reactor that comprises two reactor sections and a high-pressure condenser section placed outside the reactor. The invention also relates to a process for the preparation of urea in this installation. This involves feeding the gas stream leaving the stripper wholly or partly to the high-pressure condenser section of the installation. Preferably, a portion of the gas stream leaving the scrubber is fed to the second reactor section in the vertically placed combined reactor via an ammonia-driven ejector.

Abstract: A method of manufacturing (meth)acrylic acid includes: a reaction step of carrying out a catalytic gas-phase oxidation reaction; an absorbing step of absorbing (meth)acrylic acid from a (meth)acrylic-acid-containing mixed gas prepared in the reaction step; a refinement step of separating, refining, and recovering (meth)acrylic acid from a (meth)acrylic-acid-containing liquid prepared in the absorbing step; and a recirculation step of recirculating (meth)acrylic acid contained in a vent gas produced in the refinement step to the absorbing step and/or the refinement step.

Abstract: Oximes are prepared from ketones or aldehydes, hydrogen peroxide and ammonia. The reaction is carried out in a system of one aqueous phase and one phase of hydrocarbons inert under the reaction conditions in the presence of at least one interphase contactor and a catalyst system which consists of at least two components. A first component of the catalyst system is present in heterogeneous form and is based on titanium, silicon and oxygen and a second component is a homogeneously dissolved or suspended ammonium salt.

Abstract: The present invention relates to a process of preparing commercial quantities of glucose and/or fructose from sucrose, a process of preparing commercial quantities of glucose and a polyfructan from sucrose, a reactor for practicing same, a process of preparing commercial quantities of fructose and a polyglucan from sucrose and a reactor for practicing same.

Abstract: The present invention relates to compounds useful as catalysts in asymmetric synthesis of chiral compounds, methods for the synthesis of said catalysts, and methods for synthesizing chiral compounds with high enantioselectivity.

Abstract: A method of treating urinary incontinence in a patient in need thereof, the method comprising administering to the patient an effective amount of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol or a pharmacologically acceptable salt thereof, and pharmaceutical compositions.